ArticleObesity surgery2026
Safety of Apixaban for Postoperative Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Single-Centre Retrospective Cohort Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is still one of the major life-threatening complications that can occur after bariatric surgery. However, the question of the best post-discharge chemoprophylaxis has not yet been clarified. Direct oral anticoagulants such as apixaban offer practical advantages, but real-world safety data in bariatric populations are still evolving. This study aimed to evaluate the safety of apixaban for postoperative VTE prophylaxis after bariatric surgery in a high-volume tertiary centre.
methodsWe conducted a single-centre retrospective cohort study at the Bariatric Centre of Kafrelsheikh University Hospitals, Egypt. Adult patients who underwent primary or revisional bariatric surgery between January 1, 2022, and May 30, 2025, and received apixaban for postoperative prophylaxis were included (n = 540). Apixaban was prescribed as 2.5 mg twice daily, initiated at approximately 72 h postoperatively, and continued for 30 days. Outcomes were assessed at 30 and 90 days. The primary outcome was any adverse event (AE). Secondary outcomes included VTE, major bleeding, clinically relevant non-major bleeding (CRNMB), skin reactions, readmission, return to theatre, transfusion, and mortality.
resultsAdverse events occurred in 28/540 patients (5.2%). The most frequent event was CRNMB in 16 patients (3.0%), clinically presenting as vaginal bleeding, followed by skin rash in 12 patients (2.2%). No symptomatic VTE or major bleeding events were observed at 30 or 90 days; however, using the rule of three, the estimated upper 95% confidence bound was 5.6 per 1000, indicating that a low event risk cannot be excluded. All patients with adverse events were women (P = 0.0084).
conclusionsIn this 540-patient retrospective cohort, a 30-day course of apixaban after bariatric surgery demonstrated a favorable short-term safety profile with no observed VTE or major bleeding. These findings support apixaban as a practical option for extended post-discharge VTE prophylaxis in routine bariatric practice, with targeted counselling for sex-specific bleeding risk.
Indexed as
Identifiers
42250128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.